Alex Mayweg
InvestorManaging Director at Versant Ventures · Board director at Firefly Bio, Inc. · Board director at Bright Peak Therapeutics · Board director at Monte Rosa Therapeutics
Basel, Switzerland
Writes $100K – $5M checks · typically $1.5M
Find your path to Alex
893 people in our graph share verified history with Alex — schools, employers, funds. One of them is your warm intro.
Paul KwanunlockedAlex: together at Stanford University (2001–2003)
×4Alex: together at University of Oxford
×6Alex: together at Stanford University
Alex: together at Roche
About
Managing Director at Versant and head of Ridgeline Therapeutics, Versant's Basel-based Discovery Engine, with deep experience in drug discovery and medicinal chemistry. He previously served as global head of chemistry at Roche over a 14-year career and holds a Ph.D. in organic chemistry from Oxford, with post-doctoral training at Stanford and an undergraduate degree from Imperial College London.
Contact· self-published, not guessed
Board director at Firefly Bio, Inc.
Intro paths
→
In turn, Alex can intro founders to Firefly Bio, Inc.'s investors below.
Board director at Bright Peak Therapeutics
Intro paths
→
In turn, Alex can intro founders to Bright Peak Therapeutics's investors below.
Bright Peak Therapeutics's investors · 9
AlexandriaPasadena · since 2021BlackRockWilmington · since 2021Fidelity InvestmentsBoston · since 2021InvusNew York · since 2021Johnson & Johnson Innovation – JJDCNew BrunswickQatar Investment AuthorityDoha · since 2021RA CapitalBoston · since 2021VenrockPalo Alto · $500K – $10M checksVersant VenturesSan Francisco · $250K – $5M checks · since 2024
Co-founders at Bright Peak Therapeutics
VP
Vijaya PattabiramanCo-founder & Chief Technology Officer
JB
Jeffrey BodeScientific co-founder; Professor at ETH Zürich
Board director at Monte Rosa Therapeutics
Intro paths
→
In turn, Alex can intro founders to Monte Rosa Therapeutics's investors below.
Monte Rosa Therapeutics's investors · 8
Aisling CapitalNew YorkAmzak HealthNew YorkAvoro Capital AdvisorsNew YorkDimension CapitalSan Francisco · $1M – $10M checksGV (Google Ventures)Mountain View · $250K – $50M checks · since 2020HBM PartnersZug · $5M – $50M checksNew Enterprise Associates (NEA)Menlo Park · $200K – $40M checks · since 2020Versant VenturesSan Francisco · $250K – $5M checks · since 2020
Experience
- Versant VenturesManaging Directorcurrent2020 — presentBasel, Basel-Town, Switzerland
- Versant VenturesPartner2018 — 2020Basel Area, Switzerland
- Versant VenturesVenture Partner2017
- Versant VenturesEntrepreneur in Residence2016Basel Area, Switzerland
- Red Ridge BioPresident of the Board of Directorscurrent2022 — presentBasel, Basel, Switzerland
- Serac BiosciencesPresident of the Board of Directorscurrent2022 — presentBasel, Basel, Switzerland
- Revelio TherapeuticsChairman of the Boardcurrent2022 — present
- Bright Peak TherapeuticsBoard Membercurrent2017 — present
- Ridgeline TherapeuticsPresident and CSOcurrent2017 — presentBasel Area, Switzerland
- Enterprise TherapeuticsBoard Directorcurrent2018 — presentUnited Kingdom
- SixPeaks BioPresident of the Board of Directors2022 — 2025Basel, Switzerland
- Granite BioPresident of the Board of Directors2021 — 2024Basel, Basel, Switzerland
- Monte Rosa TherapeuticsBoard Director2018 — 2024Basel Area, Switzerland
- Black Diamond TherapeuticsBoard Director2017 — 2024Basel Area, Switzerland
- Black Diamond TherapeuticsFounding CSO2017 — 2018Basel Area, Switzerland
- RocheGlobal Head of Medicinal Chemistry | Principal Leader, VP2013 — 2016Basel Area, Switzerland
- RocheHead of Antibiotics Disease Area (Additional Responsibility) | Senior Leader2012 — 2014Shanghai & Basel
- RocheSite Head of Medicinal Chemistry | Senior Leader2011 — 2013Shanghai City, China
- RocheSection Head in Discovery Chemistry Technologies & Metabolic Diseases | Leader2011Shanghai City, China
- RocheGroup Leader, Medicinal Chemistry | Principal Scientist2009 — 2011Basel Area, Switzerland
- RocheShort Term International Assignment2010Kolkata, India
- RocheProject Leader, Medicinal Chemistry | Senior Scientist2006 — 2009Basel Area, Switzerland
- RocheProject Leader, Research Informatics (Additional Responsibility) | Senior Scientist2004 — 2006Basel Area, Switzerland
- RocheLaboratory Head, Medicinal Chemistry | Scientist2003 — 2006Basel Area, Switzerland
- The SEARLE Company Ltd.Medicinal Chemistry Placement | Research Chemist1996 — 1997Greater Chicago Area
Skills & more
Leadership9Drug Discovery99Medicinal Chemistry97Organic Synthesis71Pharmaceutical Industry51Drug Development32Infectious Diseases19Lead Change13Life Sciences40Drug Design23R&D14Organic Chemistry19
+12 more
High Throughput ScreeningOncologyVirologyChemistryCheminformaticsBiotechnologyLifesciencesBiochemistryNeurosciencePharmacologyHPLCBiomarkersLanguages English · French · German · Italian · Mandarin
From Alex's professional profile.
Deals · 3
Firefly Bio, Inc.Board seat
via Versant Ventures · filed Mar 2024 · $72M raise
Bright Peak TherapeuticsBoard seat
via Versant Ventures · filed Jun 2021 · $106.5M raise
Aset TherapeuticsBoard seat
via Versant Ventures · filed Jan 2018 · $12.1M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Investor
Antag TherapeuticsBlack Diamond TherapeuticsCimeio TherapeuticsEnterprise TherapeuticsLaunchpad Therapeutics, Inc.Matterhorn BiosciencesMonte Rosa TherapeuticsSixPeaks BioT-KnifeVector BioPharma
Sources: SEC Form D filings · curated public sources.
Colleagues at Versant Ventures
Alicia Levey
Venture Partner at Versant Ventures
Andrew Jefferson
Operating Partner at Versant Ventures
Ariel Kantor
Principal at Versant Ventures
Barbara Lubash
Managing Director at Versant Ventures
Beckie Robertson
Venture Advisor at Intuitive Ventures
Brad Bolzon
Chairman, Managing Director at Versant Ventures
Brian Atwood
Managing Director at Versant Ventures
Bryan Berg
Investor at Standard Capital
Network8
Barbara Lubash
Managing Director at Versant Ventures
Beckie Robertson
Venture Advisor at Intuitive Ventures
Brad Bolzon
Chairman, Managing Director at Versant Ventures
Brian Atwood
Managing Director at Versant Ventures
Carlo Rizzuto
Managing Director at Versant Ventures
Chandra Leo
Partner at HBM Partners
Clare Ozawa
Managing Director at Versant Ventures
Erik T. Engelson
Venture Partner at Versant Ventures
Investors connected to Alex in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Alex Mayweg?
- Managing Director at Versant and head of Ridgeline Therapeutics, Versant's Basel-based Discovery Engine, with deep experience in drug discovery and medicinal chemistry. He previously served as global head of chemistry at Roche over a 14-year career and holds a Ph.D. in organic chemistry from Oxford, with post-doctoral training at Stanford and an undergraduate degree from Imperial College London.
- Where does Alex Mayweg work?
- Alex Mayweg is Managing Director at Versant Ventures and Board director at Firefly Bio, Inc. and Board director at Bright Peak Therapeutics and Board director at Monte Rosa Therapeutics.
- What check size does Alex Mayweg write?
- Alex Mayweg typically writes checks of $100K – $5M.
- What boards does Alex Mayweg sit on?
- Alex Mayweg holds tracked board seats at Aset Therapeutics, Bright Peak Therapeutics, Firefly Bio, Inc..
- What companies has Alex Mayweg invested in?
- Investments tracked here include Antag Therapeutics, Black Diamond Therapeutics, Bright Peak Therapeutics, Cimeio Therapeutics, Enterprise Therapeutics, Launchpad Therapeutics, Inc., Matterhorn Biosciences, Monte Rosa Therapeutics, SixPeaks Bio, T-Knife, Vector BioPharma.
- Where did Alex Mayweg go to school?
- Alex Mayweg studied at Stanford University (Post Doc, Organic Chemistry); University of Oxford (D.Phil., Organic Chemistry); Imperial College London (B.Sc., Chemistry with a Year in Industry).
Same school
Also attended Stanford University2,000
Peter ThielCo-founder & Partner at Founders FundDavid SacksCo-founder & General Partner at Craft Ventures; former White House AI & Crypto CzarGarry TanPresident & CEO of Y CombinatorAlfred LinPartner at Sequoia CapitalJim BreyerFounder & CEO of Breyer CapitalMike Maples JrCo-founding Partner at Floodgate
+ 1,994 more
Also attended University of Oxford1,753
Reid HoffmanCo-founder of LinkedIn; Partner at GreylockMichael MoritzFormer Partner at Sequoia Capital; Senior Adviser at Sequoia HeritageGabriel PereyraCo-founder & President of HarveyDominic JacquessonInvestor at Index VenturesErin Price-WrightInvestor at Index VenturesJan HammerInvestor at Index Ventures
+ 1,747 more
